Say Goodbye to COPD Exacerbations: Dupixent (Dupilumab) Proves Effective in Second Phase 3 Trial, Speeding Up FDA Approval and Paving the Way to Becoming the First Biologic Treatment for COPD
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial Breaking News: Cutting Edge Treatment for COPD In a recent study, the NOTUS trial has shown that Dupixent® has met its primary endpoint with overwhelming efficacy in reducing exacerbations in patients with moderate-to-severe COPD. This breakthrough treatment has shown a 34% reduction in…